Haemonetics Corporation (HAE) Stock Forecast
Data as of Jun 16, 2026Healthcare · Current price $74.73 (-2.76%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Apr 13, 2026 | Anthony Petrone | Mizuho Securities | $70.00 | -6.3% |
| Nov 14, 2025 | Andrew Cooper | Raymond James | $90.00 | +20.4% |
| Aug 7, 2025 | Mike Matson | Needham | $68.00 | -9.0% |
| Nov 8, 2024 | Andrew Cooper | Raymond James | $120.00 | +60.6% |
| Sep 13, 2024 | Kristen Stewart | C.L. King | $116.00 | +55.2% |
| Sep 11, 2024 | Craig Bijou | Bank of America Securities | $85.00 | +13.7% |
| Jun 12, 2024 | Mike Matson | Needham | $112.00 | +49.9% |
Top Analysts Covering HAE
HAE vs Sector & Market
| Metric | HAE | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.33 | 2.24 | 2.41 |
| Analyst Count | 15 | 8 | 19 |
| Target Upside | -2.7% | +11475.0% | +17.1% |
| P/E Ratio | 38.24 | 3.99 | 31.98 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-06-27 | $328M | $333M | $336M | 5 |
| 2026-09-27 | $334M | $345M | $351M | 2 |
| 2026-12-27 | $346M | $357M | $364M | 2 |
| 2027-03-27 | $343M | $353M | $360M | 2 |
| 2027-03-29 | $1.37B | $1.39B | $1.41B | 9 |
| 2027-06-27 | $347M | $358M | $365M | 2 |
| 2027-09-27 | $362M | $373M | $380M | 2 |
| 2027-12-27 | $373M | $385M | $392M | 2 |
| 2028-03-27 | $368M | $380M | $387M | 1 |
| 2028-03-29 | $1.48B | $1.48B | $1.48B | 8 |
| 2029-03-29 | $1.52B | $1.55B | $1.57B | 1 |
| 2030-03-29 | $1.63B | $1.66B | $1.68B | 1 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-06-27 | $1.14 | $1.16 | $1.17 | 6 |
| 2026-09-27 | $1.27 | $1.32 | $1.36 | 2 |
| 2026-12-27 | $1.34 | $1.40 | $1.43 | 2 |
| 2027-03-27 | $1.35 | $1.40 | $1.44 | 4 |
| 2027-03-29 | $5.12 | $5.29 | $5.46 | 8 |
| 2027-06-27 | $1.26 | $1.31 | $1.34 | 4 |
| 2027-09-27 | $1.48 | $1.54 | $1.57 | 4 |
| 2027-12-27 | $1.51 | $1.58 | $1.61 | 4 |
| 2028-03-27 | $1.52 | $1.58 | $1.62 | 3 |
| 2028-03-29 | $5.49 | $5.91 | $6.18 | 5 |
| 2029-03-29 | $6.73 | $6.88 | $7.00 | 1 |
| 2030-03-29 | $7.59 | $7.76 | $7.90 | 1 |
Frequently Asked Questions
What is the analyst consensus for HAE?
The consensus among 15 analysts covering Haemonetics Corporation (HAE) is Buy with an average price target of $84.60.
What is the highest price target for HAE?
The highest price target for HAE is $120.00, set by Andrew Cooper at Raymond James on 2024-11-08.
What is the lowest price target for HAE?
The lowest price target for HAE is $68.00, set by Mike Matson at Needham on 2025-08-07.
How many analysts cover HAE?
15 analysts have issued ratings for Haemonetics Corporation in the past 12 months.
Is HAE a buy or sell right now?
Based on 15 analyst ratings, HAE has a consensus rating of Buy (2.33/5) with a -2.7% upside to the consensus target of $84.60.
What are the earnings estimates for HAE?
Analysts estimate HAE will report EPS of $1.16 for the period ending 2026-06-27, with revenue estimated at $333M.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.